Ally Bridge Group
Latest statistics and disclosures from Ally Bridge Group's latest quarterly 13F-HR filing:
- Top 5 stock holdings are MLTX, XENE, ITCI, AXSM, APLS, and represent 50.84% of Ally Bridge Group's stock portfolio.
- Added to shares of these 10 stocks: ITCI (+$9.1M), AXSM (+$7.7M), APLS (+$6.9M), MLTX (+$5.2M), AMLX, ARDX, Ambrx Biopharma, MRTX, PMN, MDVL.
- Started 9 new stock positions in MDVL, ITCI, Ambrx Biopharma, AXSM, AMLX, PMN, MRTX, ARDX, APLS.
- Reduced shares in these 9 stocks: Reata Pharmaceuticals Inc Cl A (-$11M), VRNA (-$10M), VRDN, MRNS, Praxis Precision Medicines I, Medavail Holdings Ord, Mdxhealth Sa Sponsored, BDTX, RPID.
- Sold out of its positions in MRNS, Mdxhealth Sa Sponsored, Medavail Holdings Ord, RPID, Reata Pharmaceuticals Inc Cl A, VRNA, VRDN.
- Ally Bridge Group was a net buyer of stock by $9.6M.
- Ally Bridge Group has $85M in assets under management (AUM), dropping by 3.19%.
- Central Index Key (CIK): 0001822947
Tip: Access up to 7 years of quarterly data
Positions held by Ally Bridge Group consolidated in one spreadsheet with up to 7 years of data
Download as csv Download as ExcelPortfolio Holdings for Ally Bridge Group
Ally Bridge Group holds 19 positions in its portfolio as reported in the September 2023 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
---|---|---|---|---|---|---|
Moonlake Immunotherapeutics Class A Ord (MLTX) | 12.3 | $10M | +100% | 183k | 57.00 |
|
Xenon Pharmaceuticals (XENE) | 10.7 | $9.1M | 267k | 34.16 |
|
|
Intra Cellular Therapies (ITCI) | 10.7 | $9.1M | NEW | 175k | 52.09 |
|
Axsome Therapeutics (AXSM) | 9.1 | $7.7M | NEW | 111k | 69.89 |
|
Apellis Pharmaceuticals (APLS) | 8.1 | $6.9M | NEW | 182k | 38.04 |
|
Cytokinetics Com New (CYTK) | 7.7 | $6.6M | 223k | 29.46 |
|
|
Merus N V (MRUS) | 6.1 | $5.2M | +11% | 221k | 23.58 |
|
Amylyx Pharmaceuticals (AMLX) | 5.9 | $5.0M | NEW | 273k | 18.31 |
|
Geron Corporation (GERN) | 5.5 | $4.7M | +4% | 2.2M | 2.12 |
|
Ardelyx (ARDX) | 4.2 | $3.6M | NEW | 881k | 4.08 |
|
Ambrx Biopharma Sponsored Ads | 3.8 | $3.2M | NEW | 281k | 11.50 |
|
Mirati Therapeutics (MRTX) | 3.6 | $3.1M | NEW | 70k | 43.56 |
|
Jasper Therapeutics | 2.6 | $2.2M | +24% | 3.1M | 0.70 |
|
Black Diamond Therapeutics (BDTX) | 2.1 | $1.8M | -20% | 634k | 2.87 |
|
Praxis Precision Medicines I | 2.1 | $1.8M | -66% | 1.1M | 1.71 |
|
Compass Therapeutics (CMPX) | 2.1 | $1.8M | 915k | 1.97 |
|
|
Context Therapeutics (CNTX) | 1.3 | $1.1M | +11% | 726k | 1.51 |
|
Promis Neurosciences Com New (PMN) | 1.2 | $1.1M | NEW | 532k | 1.98 |
|
Medavail Holdings Com New (MDVL) | 0.8 | $707k | NEW | 118k | 6.00 |
|
Past Filings by Ally Bridge Group
SEC 13F filings are viewable for Ally Bridge Group going back to 2020
- Ally Bridge Group 2023 Q3 filed Nov. 14, 2023
- Ally Bridge Group 2023 Q2 filed Aug. 14, 2023
- Ally Bridge Group 2023 Q1 filed May 15, 2023
- Ally Bridge Group 2022 Q4 filed Feb. 14, 2023
- Ally Bridge Group 2022 Q3 filed Nov. 14, 2022
- Ally Bridge Group 2022 Q2 filed Aug. 15, 2022
- Ally Bridge Group 2022 Q1 filed May 16, 2022
- Ally Bridge Group 2021 Q4 filed Feb. 14, 2022
- Ally Bridge Group 2021 Q3 filed Nov. 15, 2021
- Ally Bridge Group 2021 Q2 filed Aug. 16, 2021
- Ally Bridge Group 2021 Q1 filed May 17, 2021
- Ally Bridge Group 2020 Q4 filed Feb. 16, 2021